Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PF Form 4 July 26, 2007	HARMACEUT	FICALS INC	C/MA								
	1 /								OMB AF	PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB Number:	3235-0287			
Check the if no long		STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF								January 31,	
subject to Section 1 Form 4 o	6. STAT									2005 average rs per 0.5	
Form 5 obligation may cont <i>See</i> Instru 1(b).	ns Section 1	7(a) of the	Public Ut		ling Con	ipany	Act of	e Act of 1934, 1935 or Section 0	n		
(Print or Type F	Responses)										
POWER JOHANNA MESSINA Symbol VERTE			r Name and Ticker or Trading X PHARMACEUTICALS IA [VRTX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Month				of Earliest Transaction Day/Year) 2007				Director 10% Owner XOfficer (give title Other (specify below) below) VP & Controller			
				ndment, Date Original th/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction E (Month/Day/Ye	ar) Executio any	ned n Date, if Day/Year)	3. 4. Securities Acc Transaction(A) or Disposed Code (Instr. 3, 4 and 5 (Instr. 8) (A) or Code V Amount (D)			of (D) Securities		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	07/25/2007			M	872	A A	\$ 13.11	7,436	D		
Common Stock	07/25/2007			М	128	А	\$ 11.27	7,564	D		
Common Stock	07/25/2007			S <u>(1)</u>	1,000	D	\$ 30.19	6,564	D		
Common Stock								2,562	Ι	401(k)	

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. 5. Number Transaction		6. Date Exercisab Expiration Date	le and	7. Title and Amount of 3 Underlying Securities	
Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	-		(Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	\$ 13.11	07/25/2007		М	872	(2)	12/01/2009	Common Stock	872
Stock Option	\$ 11.27	07/25/2007		М	128	01/07/2005(3)	10/06/2014	Common Stock	128

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
POWER JOHANNA MESSINA					
O VERTEX PHARMACEUTICALS INCORPORATED VP & C			VP & Controller	ntroller	
130 WAVERLY STREET			vi a controller		
CAMBRIDGE, MA 02139					
Signatures					

Valerie L. Andrews, Attorney-In-Fact 07/26/2007

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to Ms. Messina-Power's company approved trading plan established under Rule 10b5-1.

(2) Fully vested.

I S

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

(3) Right to buy under 1996 Stock and Option Plan, vesting quarterly over 4 years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.